Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Miguel Gouveia, Gonçalo Jesus, Mónica Inês, João Costa & Margarida Borges. (2019) Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine. Human Vaccines & Immunotherapeutics 15:4, pages 850-858.
Read now
Read now
Barbara Rita Porchia, Paolo Bonanni, Angela Bechini, Gugliemo Bonaccorsi & Sara Boccalini. (2017) Evaluating the costs and benefits of pneumococcal vaccination in adults. Expert Review of Vaccines 16:2, pages 93-107.
Read now
Read now
Yiling Jiang, Frédéric Gervais, Aline Gauthier, Charles Baptiste, Prescilla Martinon & Xavier Bresse. (2015) A comparative public health and budget impact analysis of pneumococcal vaccines: The French case. Human Vaccines & Immunotherapeutics 11:9, pages 2188-2197.
Read now
Read now
Yiling Jiang, Aline Gauthier, Sam Keeping & Stuart Carroll. (2014) A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Review of Pharmacoeconomics & Outcomes Research 14:6, pages 901-911.
Read now
Read now
Articles from other publishers (7)
Fatemeh Teimouri, Abbas Kebriaeezadeh, Seyed Mohsen Zahraei, Mohammadmahdi Gheiratian & Shekoufeh Nikfar. (2017) Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran. DARU Journal of Pharmaceutical Sciences 25:1.
Crossref
Crossref
Elizabeth T. Cafiero-Fonseca, Andrew Stawasz, Sydney T. Johnson, Reiko Sato & David E. Bloom. (2017) The full benefits of adult pneumococcal vaccination: A systematic review. PLOS ONE 12:10, pages e0186903.
Crossref
Crossref
Jose Miguel Rodríguez González-Moro, Rosario Menéndez, Magda Campins, Nadia Lwoff, Itziar Oyagüez, María Echave, Javier Rejas & Fernando Antoñanzas. (2015) Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain. Clinical Drug Investigation 36:1, pages 41-53.
Crossref
Crossref
Greg L. Plosker. (2015) 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults. Drugs 75:13, pages 1535-1546.
Crossref
Crossref
Anneke Steens, Didrik F. Vestrheim & Birgitte Freiesleben de Blasio. (2015) Pneumococcal vaccination in older adults in the era of childhood vaccination: Public health insights from a Norwegian statistical prediction study. Epidemics 11, pages 24-31.
Crossref
Crossref
Francesco Saverio Mennini, Andrea Marcellusi, Patrizia Giannantoni, Stefano Valente, Alessandro Rinaldi & Elisabetta Franco. (2015) Budget impact of pneumococcal vaccination in adults and elderly in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2:1, pages GRHTA.5000193.
Crossref
Crossref
Katelijne van de Vooren, Silvy Duranti, Alessandro Curto & Livio Garattini. (2013) A Critical Systematic Review of Budget Impact Analyses on Drugs in the EU Countries. Applied Health Economics and Health Policy 12:1, pages 33-40.
Crossref
Crossref